New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:16 EDTIDRAIdera Pharmaceuticals says Phase 2 trial of IMO-8400 met primary endpoint
Idera Pharmaceuticals announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. The primary objective of the trial was to evaluate the safety and tolerability of IMO-8400 over a 12-week treatment period, with a secondary objective to evaluate the clinical activity of IMO-8400. The trial met its primary objective as all treatments were well tolerated with no treatment related discontinuation, serious adverse events or dose reductions. IMO-8400 treatment met the secondary objective of demonstrating clinical activity in patients with psoriasis, as assessed by Psoriasis Area and Severity Index. IMO-8400, which is Idera’s lead clinical candidate, is an antagonist of Toll-like receptors 7, 8, and 9. Idera’s strategy is to develop IMO-8400 for the treatment of genetically defined forms of B-cell lymphoma and orphan autoimmune diseases.
News For IDRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 23, 2015
09:27 EDTIDRAIdera Pharmaceuticals Chief Medical Officer resigns
Idera Pharmaceuticals disclosed in a regulatory filing that Louis Brenner, M.D. resigned his positions as senior VP and Chief Medical Officer of Idera to accept a new role as the Chief Operating Officer of a privately-held biotechnology company. This change will become effective April 3.
March 12, 2015
08:19 EDTIDRAIdera Pharmaceuticals reports Q4 EPS (14c), two estimates (11c)
Reports Q4 revenue $2K, two estimates $60.00K.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use